vs
Side-by-side financial comparison of AETHLON MEDICAL INC (AEMD) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
iRhythm Holdings, Inc. is the larger business by last-quarter revenue ($208.9M vs $60.0K, roughly 3483.6× AETHLON MEDICAL INC). iRhythm Holdings, Inc. runs the higher net margin — 2.7% vs -2926.4%, a 2929.1% gap on every dollar of revenue. iRhythm Holdings, Inc. produced more free cash flow last quarter ($14.5M vs $-2.0M).
Aethlon Medical Inc. is a clinical-stage medical technology firm that develops targeted therapeutic devices to address life-threatening health conditions. Its lead product, the Hemopurifier, is designed to remove harmful viruses, cancer-derived exosomes, and other pathogens from the bloodstream. The company primarily operates in the infectious disease and oncology healthcare segments, with main market presence in North America.
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
AEMD vs IRTC — Head-to-Head
Income Statement — Q3 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $60.0K | $208.9M |
| Net Profit | $-1.8M | $5.6M |
| Gross Margin | — | 70.9% |
| Operating Margin | -3026.4% | 1.1% |
| Net Margin | -2926.4% | 2.7% |
| Revenue YoY | — | 27.1% |
| Net Profit YoY | 49.4% | 518.5% |
| EPS (diluted) | $-10.05 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $208.9M | ||
| Q3 25 | — | $192.9M | ||
| Q2 25 | — | $186.7M | ||
| Q1 25 | — | $158.7M | ||
| Q4 24 | $60.0K | $164.3M | ||
| Q3 24 | $95.1K | $147.5M | ||
| Q2 24 | — | $148.0M | ||
| Q1 24 | — | $131.9M |
| Q4 25 | — | $5.6M | ||
| Q3 25 | — | $-5.2M | ||
| Q2 25 | — | $-14.2M | ||
| Q1 25 | — | $-30.7M | ||
| Q4 24 | $-1.8M | $-1.3M | ||
| Q3 24 | $-2.8M | $-46.2M | ||
| Q2 24 | — | $-20.1M | ||
| Q1 24 | — | $-45.7M |
| Q4 25 | — | 70.9% | ||
| Q3 25 | — | 71.1% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 68.8% | ||
| Q4 24 | — | 70.0% | ||
| Q3 24 | — | 68.8% | ||
| Q2 24 | — | 69.9% | ||
| Q1 24 | — | 66.3% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | -4.4% | ||
| Q2 25 | — | -10.0% | ||
| Q1 25 | — | -20.5% | ||
| Q4 24 | -3026.4% | -2.5% | ||
| Q3 24 | -3050.2% | -34.1% | ||
| Q2 24 | — | -15.5% | ||
| Q1 24 | — | -28.9% |
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | -2.7% | ||
| Q2 25 | — | -7.6% | ||
| Q1 25 | — | -19.3% | ||
| Q4 24 | -2926.4% | -0.8% | ||
| Q3 24 | -2950.2% | -31.3% | ||
| Q2 24 | — | -13.6% | ||
| Q1 24 | — | -34.6% |
| Q4 25 | — | $0.18 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.44 | ||
| Q1 25 | — | $-0.97 | ||
| Q4 24 | $-10.05 | $-0.03 | ||
| Q3 24 | $-16.11 | $-1.48 | ||
| Q2 24 | — | $-0.65 | ||
| Q1 24 | — | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.8M | $583.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3M | $152.7M |
| Total Assets | $6.5M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $583.8M | ||
| Q3 25 | — | $565.2M | ||
| Q2 25 | — | $545.5M | ||
| Q1 25 | — | $520.6M | ||
| Q4 24 | $4.8M | $535.6M | ||
| Q3 24 | $6.9M | $522.0M | ||
| Q2 24 | — | $561.5M | ||
| Q1 24 | — | $569.1M |
| Q4 25 | — | $152.7M | ||
| Q3 25 | — | $121.9M | ||
| Q2 25 | — | $103.7M | ||
| Q1 25 | — | $86.7M | ||
| Q4 24 | $4.3M | $90.9M | ||
| Q3 24 | $6.0M | $71.8M | ||
| Q2 24 | — | $99.2M | ||
| Q1 24 | — | $90.3M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $995.2M | ||
| Q2 25 | — | $964.0M | ||
| Q1 25 | — | $926.1M | ||
| Q4 24 | $6.5M | $931.4M | ||
| Q3 24 | $8.8M | $909.7M | ||
| Q2 24 | — | $919.2M | ||
| Q1 24 | — | $909.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $26.2M |
| Free Cash FlowOCF − Capex | $-2.0M | $14.5M |
| FCF MarginFCF / Revenue | -3357.0% | 6.9% |
| Capex IntensityCapex / Revenue | 3.7% | 5.6% |
| Cash ConversionOCF / Net Profit | — | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.2M | ||
| Q3 25 | — | $34.9M | ||
| Q2 25 | — | $27.7M | ||
| Q1 25 | — | $-7.9M | ||
| Q4 24 | $-2.0M | $19.2M | ||
| Q3 24 | $-2.2M | $24.3M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | $-52.0M |
| Q4 25 | — | $14.5M | ||
| Q3 25 | — | $20.1M | ||
| Q2 25 | — | $17.3M | ||
| Q1 25 | — | $-17.3M | ||
| Q4 24 | $-2.0M | $12.4M | ||
| Q3 24 | — | $15.5M | ||
| Q2 24 | — | $3.4M | ||
| Q1 24 | — | $-61.8M |
| Q4 25 | — | 6.9% | ||
| Q3 25 | — | 10.4% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | -10.9% | ||
| Q4 24 | -3357.0% | 7.5% | ||
| Q3 24 | — | 10.5% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | -46.8% |
| Q4 25 | — | 5.6% | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | — | 5.9% | ||
| Q4 24 | 3.7% | 4.2% | ||
| Q3 24 | 0.0% | 6.0% | ||
| Q2 24 | — | 5.7% | ||
| Q1 24 | — | 7.4% |
| Q4 25 | — | 4.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AEMD
Segment breakdown not available.
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
